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photodynamic therapy in oral 
lichen planus: A prospective  
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Raluca cosgarea1,2,7*, Robert pollmann3,7, Jusra Sharif1, Thomas Schmidt3, Ronja Stein3, 
Aura Bodea4, Thorsten Auschill1, Anton Sculean5, Rüdiger eming3, Brandon Greene6, 
Michael Hertl3,8 & nicole Arweiler1,8
Oral lichen planus (OLP) is a common, chronic relapsing inflammatory disorder of the mucous 
membranes, which causes major discomfort. Current treatment includes topical/systemic 
glucocorticoids, immune modulators and systemic immunosuppressants, which may lead to 
considerable side-effects. The aim of this study was to determine the clinical and immunological efficacy 
of photodynamic therapy (PDT) in OLP as an alternative, easy-to-use, safe and non-invasive treatment. 
Twenty patients with OLP were treated with PDT in a prospective case-controlled pilot-study. PDT 
was performed on the most extensive oral lesion in 4 sessions (day 1, 3, 7, 14). Peripheral blood and 
lesional T cells were analysed before (day 1) and after PDT treatment (day 28). PDT led to a statistically 
significant reduction of clinical parameters (lesion size, ABSIS, Thongprasom-score) and improvement 
of all evaluated quality-of-life (QOL) items. The clinical improvement was accompanied by a significant 
decrease of the relative number of CD4+ and CD8+ T cells in mucosal OLP-lesions. Furthermore, 
CXCL10 plasma levels were decreased and the number of activated peripheral CD4 + CD137+ and 
CD8 + CD137+ T cells and IL-17-secreting T cells was diminished. PDT treatment in OLP leads to lesion 
reduction and improvement of QOL, and induces local and systemic anti-inflammatory effects. The 
study identifies PDT as a novel therapeutic option in OLP.
Lichen planus (LP) is a common T cell mediated, chronic inflammatory disorder which affects the oral mucosa 
and causes major discomfort, its etiology is still not entirely elucidated1–4. Oral LP (OLP) affects the buccal 
mucosa, tongue and gingiva, and usually presents with symmetrical, bilateral or multiple lesions5,6. The erosive 
and atrophic forms may present with remarkable burning and pain sensations that restrict food intake and perfor-
mance of oral hygiene measures leading to weight loss, nutritional deficiencies7,8, loss of teeth and function with a 
major impact on the quality of life (QOL). These OLP forms are often resistant to treatment9,10 and have a higher 
tendency to malignant transformation11,12.
At present, topical corticosteroids are widely accepted as the primary choice of OLP therapy, but other thera-
peutical protocols have also been investigated, i.e. topical and systemic retinoids, calcineurin inhibitors, aloe-vera, 
and thalidomide6,7,13–25. However, some of these treatment options proved to be ineffective or only partially effec-
tive12. Photodynamic therapy (PDT) as an easy-to-use and safe treatment option induces cell and tissue damage 
by combining the use of a photosensitizer and light that activates the photosensitizer by exposure to low-level 
visible light in an appropriate wavelength. The general principle of PDT was first described in 1900 by the work 
of Raab and Tappeiner who evaluated the effects of acridine on malaria-causing protozoa showing a lethal effect 
of this combination on a species of paramecium (Infusoria)26. They discovered the optical property of fluores-
cence and that one of its products was responsible for the cytotoxic effects in vitro which relies on the energy 
transfer from light to the chemical, similar to the plants (light-chlorophyll absorbtion). This effect was later 
applied by Tappeiner and Jesionek for the treatment of skin cancers and described the therapy as “photodynamic 
1Department of Periodontology, Philipps-University Marburg, Marburg, Germany. 2Clinic for Prosthodontics, 
University of Medicine and Pharmacy, Faculty of Dentistry “Iuliu Hatieganu”, Cluj-Napoca, Romania. 3Department 
of Dermatology und Allergology, Philipps-University Marburg, Marburg, Germany. 4Periodontal Private Practice, 
Cluj-Napoca, Romania. 5Department of Periodontology, University of Bern, Dental School, Bern, Switzerland. 
6Institute of Biometry and Statistics, Philipps-University Marburg, Marburg, Germany. 7These authors contributed 
equally: Raluca Cosgarea and Robert Pollmann. 8These authors jointly supervised this work: Michael Hertl and Nicole 
Arweiler. *email: ralucacosgarea@gmail.com
open
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
6
8
2
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
2Scientific RepoRtS |         (2020) 10:1667  | https://doi.org/10.1038/s41598-020-58548-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
phenomenon”27. For the successful inactivation of bacteria, Jodlbauer and Tappeiner, and Huber demonstrated 
that oxygen was a prerequisite for the photosensitization reactions28,29. Based on these early studies PDT was then 
used for the treatment of actinic keratosis and various types of skin cancers (such as basal cell carcinoma) and in 
the past 15 years for the treatment of OLP.
The human tissue transmits efficiently red light and this combined with a longer activation wavelength of a 
photosensitizer leads to a deeper light penetration30. Most photosensitizers allow a light penetration of 0.5 cm (for 
630 nm) to 1.5 cm (for ab. 700 nm)31,32. According to these properties, the therapeutical effect of various photo-
sensitizers is defined for different pathological conditions and tumors. Thus, for each tissue and photosensitizer a 
different total light dose, dose rate and tissue destruction is achieved30. Light radiation in a specific wavelength for 
the photosensitizer, sends the photosensitizer from a low-energy ground state to an excited singlet state. This may 
afterwards undergo a transition to a higher energy triplet state which reacts with the endogenous oxygen. Thus, 
singlet oxygens and cytotoxic free radicals are released and determine membrane lysis, destruction of targeted 
cells, and inactivation of proteins13,22. The cytotoxic effects of PDT rely on the fact that during light radiation, 
photosensitizers that localize in lysosomes and cell membranes induce necrosis, while those penetrating mito-
chondria lead to apoptosis33. Additionally, PDT seems to induce complex inflammatory and immune responses34. 
In murine tumor models a strong invasion of neutrophils, mast cells and monocytes had been observed during 
and after PDT35 accompanied by activation of specific T-lymphocytes36 and apoptosis in the hyperproliferating 
inflammatory cells37,38.
PDT has been increasingly used for treating various types of oral cancer, mucosal hypertrophy, leukoplakia 
or erythroplakia showing no to optimal efficacy (no response to treatment to complete remission)39–43. A few 
studies investigated the efficacy of PDT in reducing the clinical symptoms of OLP, i.e. lesion size and symptoms, 
and found mixed clinical responses22,44–49. Furthermore, limited evidence exists regarding the histological, immu-
nological effects of PDT in OLP. The aim of this study was to determine the efficacy of PDT in OLP based on the 
combination of clinical and immunological parameters. The results show a reduction of lesion size and decrease 
of ABSIS and Thongprasom scores and an improvement of QOL parameters. These effects are accompanied 
by a decrease of CD4+, CD8+ and IL-17+ cells in OLP lesions. In peripheral blood, PDT induces a decrease of 
CD4+CD137+ and CD8+CD137+ and IL-17+ T cells and CXCL10 plasma levels.
Results
PDT treatment is accompanied by clinical amelioration of OLP. Mucosal lesions of 20 patients with 
OLP were treated with PDT within 14 days (4 sessions; day 1, 3, 7, and 14; Fig. 1) and clinical parameters were 
assessed at day 1 (baseline) and day 28, 42, and 56. PDT treatment led to a highly significant size (P < 0.001) 
reduction of the mucosal lesion starting from 14 days after PDT (day 28; Fig. 2a,c) that correlated with a sig-
nificant improvement of the ABSIS I score (P < 0.05) at days 42 and 56 (Fig. 2b). Stratification of patients with 
moderate (≤5 years; n = 9) and long-lasting disease duration (>5 years; n = 11, see Table 1) showed a similar 
reduction of the lesion size and ABSIS I scores though statistical differences could not be detected due to the 
reduced patient numbers in the groups (see Supplementary Fig. S1). Six weeks after PDT (day 56), two scores 
reflecting treatment efficacy50,51 showed a shift from more severe lesions (Thongprasom score 3,4,5) to lesions 
with softer forms (score 1,2,3) or to complete/partial remission (Carrozzo-Gandolfo score) in the majority of 
patients (Table 2). At day 56, all evaluated items for QOL showed improvements. Statistically significant however, 
was the decrease of the burning sensation and self-performed oral hygiene (Fig. 2d, P = 0.003) in concordance 
with decreasing ABSIS II scores at follow-ups compared to baseline (Fig. 2e, P = 0.005) which was most promi-
nent in patients with long-lasting disease duration (see Supplementary Fig. S1).
PDT determines an insignificant reduction of the oral bacteria. Two weeks after the final PDT ses-
sion (day 28), There was a quantitative reduction of the majority of the investigated oral bacteria. Nevertheless, 
none was significantly reduced (Table 3).
PDT leads to a decrease of peripheral CD4+CD137+ and CD8+CD137+ and IL-17+ T cells and CXCL10 
plasma levels. Fourteen days after the last PDT treatment (day 28), relative numbers of peripheral blood 
CD4+ T cells or CD8+ T- cells remained stable (Fig. 3a,b). Additionally, the relative numbers of CD4+ and CD8+ 
Figure 1. Time line of PDT treatment. Clinical and QOL parameters were assessed on day 1 (D1; before 
therapy), day 28 (D28, 14 days after therapy), day 42 (D42, 28 days after therapy) and day 56 (D56; 42 days after 
therapy). Samples were collected at D1 and D28. PDT, photodynamic treatment; QOL, quality of life.
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T- cells expressing the skin-homing factor CCR4 were not altered. In contrast, after PDT treatment, the relative 
numbers of CD137+ (activated) CD4+ and CD8+ cells were significantly decreased (Fig. 3a,b). Furthermore, 
the relative number of peripheral γδ+ T- cells was significantly increased whereas the relative number of 
CD4+CD25+CD127low T regulatory cells remained unaffected (Fig. 3c). ELISpot analysis revealed a consistent 
number of peripheral blood Th1 (IFNγ+) and Th2 (IL-5+) cells after PDT while peripheral Th17 (IL-17a+) cells 
declined (P = 0.061; Fig. 3d). CCL5 plasma levels were unaffected whereas CXCL10 plasma concentrations were 
significantly decreased (Fig. 3e). CXCL8 plasma levels were below the detection limit (data not shown). In con-
trast, in saliva of treated OLP patients, CXCL8 concentrations were slightly but not significantly lowered (Fig. 4). 
CCL5 and CXCL10 saliva concentrations were below the detection limit (data not shown).
Figure 2. PDT leads to clinical amelioration of OLP. (a) PDT induces a reduction of lesion size over time (D1-
D56). (b) PDT leads to reduction of ABSIS score I over time (D1-D56). (c) Photographically documentation of 
lesion size reduction over time (D1-D56). (d) PDT leads to a reduction of ABSIS II score over time (D1-D56). 
(e) QoL parameters (burning, pain, food, oral hygiene) are improved after PDT treatment (D1-D56). *p < 0.05, 
**p < 0.01, ***p < 0.001. PDT, photodynamic treatment; QOL, quality of life.
No. of subjects (n) 20
Gender male/female (n) 3/17
Age (years) 62 ± 8.66
Disease duration (no. patients)
<1 year 1
1–5 years 8
5–10 years 2
>10 years 9
Location of treated OLP lesion
Lining of mucosa cheek 6
Gingiva 14
Table 1. Clinical description of the studied patient cohort with OLP.
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PDT leads to a reduction of infiltrating CD4+ and CD8+ T- cells in mucosal lesions. Immuno-
histologically, mucosal lesions of OLP showed the characteristic T cell-dominated subepidermal band-like infil-
trate (Fig. 5a). Lesional CD4+ T- cells were widely spread in the upper dermis, particularly at the perivascular 
region, while lesional CD8+ T -cells were mainly located in a band-like pattern along the basal membrane zone 
(BMZ). IL-17a+ T -cells were also found along the BMZ and at the perivascular regions (Fig. 5a) as recently 
described52. After PDT, the CD3+ lesional T- cell infiltrate was markedly but not significantly diminished at day 
28, while the relative numbers of skin infiltrating CD4+ T cells and CD8+ T- cells were significantly decreased 
(Fig. 5b–d). Of note, PDT led to an altered redistribution of dermal CD8+ T- cells from the BMZ to the perivas-
cular area (Fig. 5d). Notably, the relative number of IL-17a+ cells was significantly increased in mucosal lesions 
after PDT treatment (Fig. 5e).
Discussion
PDT treatment led to a highly significant reduction of the size of OLP lesions, also reflected by a significant 
decrease of the ABSIS scores. Moreover, treatment efficacy was evident by the increasing numbers of mucosal 
lesions showing complete remission (day 28: 10%; day 56: 35%), also reflected by decreasing Thongprasom scores 
at day 56 compared to baseline (Table 2). These results are in concordance with reports by others who used PDT 
in treating OLP and showed marked improvement of the lesion size22,45–47,49,53. Furthermore, the results of our 
study show a marked improvement of all investigated QOL parameters. Specifically, there was a statistically sig-
nificant improvement of the burning sensation and oral hygiene measures as early as 6 weeks after PDT treatment 
extending previous observations showing improvement QOL parameters upon PDT treatment13,45,46,49. However, 
Variables day 1 day 28 day 42 day 56
Thongprasom score N (%)
Score 0 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Score 1 0 (0%) 1 (5%) 4 (20%) 6 (30%)
Score 2 0 (0%) 8 (40%) 9 (45%) 11 (55%)
Score 3 5 (25%) 9 (45%) 7 (35%) 3 (15%)
Score 4 11 (55%) 2 (10%) 0 (0%) 0 (0%)
Score 5 4 (20%) 0 (0%) 0 (0%) 0 (0%)
Carrozzo-Gadolfo score N (%)
Complete remission — 2 (10%) 5 (25%) 7 (35%)
Partial remission — 14 (70%) 13 (65%) 12 (60%)
No response — 4 (20%) 2 (10%) 1 (5%)
Table 2. Evaluation of treatment response according to Thongprasom, and Carrozzo and Gandolfo scores50,51.
Oral bacteria
p-value between  
timepointsT1-T4
A. actinomycetemcomitans 1.000
A. viscosus 1.000
T. forsythia 0.689
C. rectus 0.500
T. denticola 0.506
E. corrodens 0.219
P. intermedia 0.376
P. micra 0.126
P. gingivalis 0.627
F. nucleatum 1.000
A. odontolyticus 0.501
Capnocytophaga sp. 1.000
C. concisus 0.727
E. nodatum 1.000
S constellatus group 0.109
C. gracilis 0.500
S. mitis group 0.252
P. nigrescens 0.291
S. gordonii group 0.508
V. parvula 1.000
Table 3. Comparison of the microbial load (oral bacteria) before and after PDT.
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lesion size reduction alone may be a difficult parameter to assess since OLP lesions have irregular forms, and 
variable clinical phenotypes, i.e. atrophic or/and erosive areas within the same lesion.
Major efforts have been made to develop and validate clinical markers for mucosal lesions in OLP including 
individual scoring systems53 and measurement of lesions with calipers or periodontal probes46 and /or scored the 
lesions using the Thongprasom score5,13,45–47,49. To address this issue, we sought to standardize the measurement 
of OLP lesions by a computer software using clinical photographs on one hand, and by measuring the lesions in 
two directions (horizontally and vertically) related to fixed intraoral reference points on the other hand. In con-
trast to previous studies, only one oral lesion per patient was treated to give a single value per lesion size per time 
point45,46,53. This may have been a drawback of the study, when considering the parameter QOL.
The effect of PDT on the oral microbiome has been only minimally investigated. Reports based on studies 
in mice54,55 and humans56,57 have shown that photobiomodulation (therapeutical application of low levels of red 
and/or near-infrarated light) may positively affect the human microbiome54. Additionally, studies investigating 
the effect of antibacterial PDT on oral bacteria have shown that various photosensitizers may exercise various 
Figure 3. PDT induces systemic anti-inflammatory effects in OLP. (a) Relative number of CD137 expressing 
peripheral blood CD4+ T- cells is decreased 14 days after PDT treatment. Results based on analysis by flow 
cytometry. (b) Relative number of CD137 expressing peripheral blood CD8+ T- cells is decreased 14 days after 
PDT treatment. Results based on analysis by flow cytometry. (c) PDT leads to an increase of the relative number 
of peripheral blood γδ T cells. Results based on analysis by flow cytometry. (d) Number of peripheral blood IL-
17a producing T cells is decreased 14 days after PDT treatment. Results based on ELISpot. analysis. (e) CXCL10 
plasma levels are decreased 14 days after PDT treatment. Results based on ELISA analysis.*p < 0.05, **p < 0.01. 
PDT, photodynamic treatment.
Figure 4. CXCL8 saliva levels are slightly decreased after PDT treatment. Shown are saliva concentrations 
(pg/ml) of CXCL8 before (day 1, D1) and after (day 28, D28) PDT treatment of oral OLP lesions.
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effects on  oral pathogens inducing selective biofilm inactivation58,59. Nonetheless, debatable is its efficiency in the 
deeper parts of the oral biofilm since bacteria embedded in biofilms provide a higher tolerance towards antimi-
crobials60,61. In the present study, bacterial analysis of 18 oral pathogens (A. actinomycetemcomitans, A. viscosus, T. 
forsythia, C. rectus/showae, T. denticola, E. corrodens, P. intermedia, P. micra, P. gingivalis, F. nucleatum, A. odontol-
yticus, Capnocytophaga sp., C. concisus, E. nodatum, S. constellatus group, C. gracilis, S. mitis group, P. nigrescens, S. 
gordonii group, V. parvula) was performed from saliva samples before and (Table 3) two weeks after PDT. Despite 
a reduction of the majority of bacteria, none was statistically significantly reduced two weeks after therapy. Thus, 
in the present study, a significant influence of the oral microbiome by PDT cannot be admitted.
Clear guidelines regarding the recommended photosensitizer or the duration of PDT exposure are currently 
not available. Some authors used 8 applications in 1 month with 50 µl toluidine blue (1 mg/ml) combined with 
laser irradiation for 2.5 min (fluence: 1.5 J/cm2, power density: 10 mW/cm2, 630 nm)46. Others used a 5% meth-
ylene blue solution combined with diode laser irradiation (power density: 100–130 mW/cm2, 660 nm) with 8 
applications in 2 month49 or with a different light source (LED light, 630 nm, power 7.2–14.4 J/cm2) with 4 apli-
cations (days 1, 4, 7 and 14) at different doses with 120 J/cm2 45,46. We here used 4 applications of PDT within 2 
weeks (days 1, 3, 7, and 14) and chose phenothiazine chloride as photosensitizer combined with a low level laser 
(fluence: 2.49 J/cm2, power density: 200 mW/cm2, 660 nm).
PDT was used in the present study based on the so far proven cytotoxic effects, and the induced complex 
inflammatory and immune responses33–38. PDT treatment led to a significant reduction of the dermal CD4+ and 
CD8+ T- cellular infiltrate in OLP lesions which was merely visible on day 28, indicating a diminished inflamma-
tory cell infiltrate. However, whether PDT treatment has a direct impact on lesional T- cells in OLP or whether 
this observation is a consequence of an overall PDT-mediated reduced inflammatory process, still needs to be 
Figure 5. PDT induces local anti-inflammatory effects in OLP. (a) Overview of immunohistochemical 
staining of mucosal tissue sections with a lesional T- cell infiltrate before and after PDT treatment (D1, D28). 
(b–d) Relative number of lesional CD3+, CD4+ and CD8+ cells are decreased 14 days after PDT treatment. 
(e) Relative number of lesional IL-17+ cells is increased 14 days after PDT treatment. **p < 0.01. PDT, 
photodynamic treatment.
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further analyzed. Of note, the number of IL-17a-producing lesional T- cells was increased after PDT treatment. 
This finding is in contrast to a recent observation by our group which suggests that Th1/Th17 cells in lichen 
planus are pathogenic52. However, recent reports demonstrate that PDT treatment by itself can induce Th17 cell 
accumulation62. As peripheral blood IL-17a+ T -cells were decreased after PDT treatment, this may have been the 
consequence of a transmigration of anti-inflammatory Th17 cells from peripheral blood into the mucosal tissue 
upon resolution of PDT-induced mucosal inflammation. Further studies are needed to elucidate the functional 
phenotype of Th17 cells after PDT treatment in OLP. Along this line, Th17 cells and their associated cytokine 
IL-17a were elevated in the peripheral blood of OLP patients and were also detected in OLP lesions63–67. Under 
non-inflammatory conditions, Th17 cells are critical for the induction of innate and adaptive host responses at 
mucosal areas and show a great deal of plasticity with pro- and anti-inflammatory functions68. Thus, Th17 trans-
migration in peripheral blood may point towards a transformation towards an anti-inflammatory phenotype. 
In contrast to peripheral blood IL-17a+ T- cells, the relative number of peripheral γ/δ+ T- cells was found to be 
increased after PDT. As γδ T- cells were also sparsely detected in OLP lesions69, their elevated numbers in the 
periphery subsequent to a reduction of local inflammation suggests a rather pro-inflammatory function.
CCL5 and CXCL10 were described as central chemokines for the recruitment of T- cells into OLP lesions70,71. 
Strikingly, 14 days after PDT treatment of single mucosal lesions, serum levels of CXCL10 were significantly 
reduced. This is in line with the finding that lesional CD8+ T- cells, which had been described as a main producer 
of CXCL1071, were significantly decreased after PDT treatment.
PDT leads to a significant decrease of peripheral blood CD4+CD137+ and CD8+CD137+ T- cells in OLP 
patients indicating a systemic anti-inflammatory effect of PDT with a direct impact on activated CD4+ and CD8+ 
T- cell subsets, which are presumably critical in the OLP pathogenesis72. CD137 (4-1BB) is a co-stimulatory sur-
face molecule expressed on various immune cells including antigen-activated T- cells73–75. The natural counter 
receptor 4-1BBL is up-regulated on activated antigen-presenting cells particularly on dendritic cells73. CD137 
ligand-mediated co-stimulation of human T- cells induces CD4+ and CD8+ T- cell expansion, cytokine release 
and cytolytic effector mechanisms74. The detection of CD137 expression by flow cytometry is described as an 
effective assay for the detection of alloreactive T cells76 and therapies targeting CD137 showed anti-inflammatory 
effects in autoimmune diseases77–79.
Nonetheless, in order to evaluate the real benefit of PDT as compared to other phototherapies and to deter-
mine the therapeutic effect of a photosensitizer in OLP, in future studies a control group treated with photobio-
modulation at a similar wavelength and power density but without a dye may be taken into consideration.
In conclusion, PDT leads to a significant improvement of clinical and QOL parameters in OLP which are 
associated with local and systemic anti-inflammatory effects. PDT holds promise as a novel therapeutic option in 
OLP and may deliver new insights for a better understanding of OLP pathogenesis in general.
Methods
Study design and OLP patient cohort. Forty-three patients with OLP were screened for participation 
in this prospective, case-controlled, clinical intervention trial. Inclusion criteria were: histologically proven OLP 
with a minimal lesion size of 10 mm, age >18 years. Exclusion criteria were pregnancy, renal insufficiency, HIV-, 
hepatitis C, and untreated heart disease. Finally, 20 eligible patients (mean age: 62 ± 8.66 years, 17 female, 2 
smokers) gave their informed written consent to participate in the study (Table 1;) approved by local Ethical 
Committee Philipps University Marburg, Germany; identification AZ:57/14, approval on 22.07.2014). The study 
has also been registered in the publicly accessible primary german register DRKS (Deutsches Register Klinischer 
Studien, registration date 01.07.2019, number DRKS00017540). The study was conducted according to the 
Declaration of Helsinki (1964, revision 2008) and all study procedures were performed in accordance with its 
guidelines and regulations.
Study protocol and evaluated parameters. The most extensive oral lesion was chosen for treatment 
with PDT which was performed in 4 sessions at days 1, 3, 7, and 14 as shown in Fig. 1. In detail, HELBO® Blue 
Photosensitizer* was applied and left for 3 min on a previously dried mucosal OLP lesion. After thorough rins-
ing with sterile saline solution, the lesion was irradiated with a spot probe (HELBO® 2D Spot Probe*) for 30 s/
spot (active surface of the spot 19 mm2) using a low level laser (HELBO® TheraLite Laser, Bredent® Medical 
GmbH&Co.KG, Senden, Germany) at an output power of 200 mW/cm2 and at an emission of 660 nm.
Lesions were measured and scored at baseline (prior to first PDT; day 1) and 2, 4 and 6 weeks after the last 
PDT session (day 28, 42, and 56). Lesion size was measured horizontally and vertically at the nearest 0.5 mm with 
a periodontal probe (PCP UNC-15, Hu-Friedy) and with an image measuring software (ImageJ2) using clinical 
photographs. Lesions were scored using the Thongprasom score50 (0: no lesion, normal mucosa; 1: mild white 
striae, no erythematous area; 2: white striae with atrophic area <1 cm2; 3: white striae with atrophic area ≥1 cm2; 
4: white striae with erosive area <1 cm2; 5: white striae with erosive area ≥1 cm2). Treatment evaluation were 
scored after PDT (day 28, 42, and 56) as proposed by Carozzo and Gandolfo51 (complete remission: disappearance 
of all ulcerative lesions with/without remaining mild striae; partial response: improvement without complete 
healing of the ulcerative lesions; no response: worsening or absence of any improvement of the lesions).
Additionally, the Autoimmune Bullous Skin Disorder Intensity Scores80 (ABSIS) I and II were determined. 
Moreover, at baseline and 6 weeks after therapy, QOL was assessed for the items pain, burning sensation, impaired 
food intake and self-performed oral hygiene by means of a Visual Analogue Scala (VAS; 0: no symptom, 10: very 
severe pain/strong impairment).
Laboratory analyses. For performing flow cytometry, CPDA-treated peripheral blood samples from OLP 
patients before and 14 days after PDT therapy were stained for 30 min at 4 °C with the following monoclonal anti-
bodies: mouse-anti human CD3-PE-Cy5 (UCHT1), mouse anti-human CD3-APC (UCHT1), mouse anti-human 
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CD4-FITC (RPA-T4), mouse anti-human CD8-FITC (SK1), mouse anti-human CD25-APC (M-A251), mouse 
anti-human CD127-PE (HIL-7R-M21), mouse anti-human CD137 (4B4-1), mouse anti-human TCR-γδ (B1), 
mouse IgG1-FITC (MOPC-21), mouse IgG1-PE (G18-145), mouse IgG1-PE-Cy5 (MOPC-21), mouse IgG1-APC 
(G18-145) (all Becton Dickinson, Franklin Lakes, USA), mouse anti-human CCR4-APC (205410), mouse 
IgG2-APC (133303) (all R. & D. Systems, Minneapolis, USA). Red blood cells were lysed by ACK lysis buffer 
(0.15 M NH4Cl, 1 mM KHCO3 and 0.1 mM EDTA). Subsequently, cells were washed twice (PBS, 1% BSA, 0.1% 
NaN3), resuspended and analysed by FACS (FACSCalibur, Becton Dickinson, Franklin Lakes, USA). FCS-files 
were analyzed by FlowJo 7.6 single cell analysis software (FlowJo LLC, Ashland, USA).
The Enzyme-linked immunospot (ELISpot) assays were performed as previously described81. IFNγ-, IL-5- 
and IL-17A- positive spots were developed according to the manufacturers’ instructions (Human IFNγ-ELISpot, 
Human IL-5-ELISpot, Becton Dickinson, Franklin Lakes, US; Human IL-17A ELISpot Ready-Set-Go, eBio-
science, San Diego, US). The ELISpot plates were analysed by an ELISpot plate reader (A.EL.VIS, Hannover, 
Germany).
For performing the Enzyme-linked immunosorbent assay (ELISA), Citrate phosphate dextrose adenine 
(CPDA)-treated peripheral blood and saliva samples were centrifuged, and plasma and saliva supernatants were 
collected and stored at −20 °C. Saliva was collected by spitting method82. Saliva was allowed to accumulate and 
the patients spat every 60 sec over 5 min into a collection tube. Saliva concentrations of the chemokines CCL5, 
CXCL10 and IL-8 were determined by commercial ELISA (all Biolegend, San Diego, USA).
From the saliva samples collected as previously described, quantitative microbial analysis of 18 oral bacteria 
(A. actinomycetemcomitans, A. viscosus, T. forsythia, C. rectus/showae, T. denticola, E. corrodens, P. intermedia, P. 
micra, P. gingivalis, F. nucleatum, A. odontolyticus, Capnocytophaga sp., C. concisus, E. nodatum, S. constellatus 
group, C. gracilis, S. mitis group, P. nigrescens, S. gordonii group, V. parvula) was performed prior and two weeks 
after therapy by means of real-time PCR using a commercially available test (Firma Greiner Bio-One, Solingen, 
Germany).
Immunochemistry was conducted on paraffin-embedded skin sections that were processed for immuno-
histochemistry as recently described52. Primary antibodies used were mouse anti-human CD3, CD4, CD8 (all 
Novocastra, Leica, Wetzlar Germany); rabbit anti-human IL-17A (Novus, Littleton, Co, USA). Secondary anti-
bodies were based on Bond Polymer Refine Detection Kit (Leica, Wetzlar Germany) biotinylated anti-mouse 
IgG, biotinylated anti-rabbit IgG (Vector Laboratories; Burlingame, CA, USA). Secondary antibodies were subse-
quently detected by peroxidase- or alkaline phosphatase-labeled ABC-systems (Dako). Visualization was carried 
out using 3,3’-diaminobenzide (DAB; Dako) as chromogene. The T cell infiltrate of skin biopsies were quantified 
by microscopical images (Axiostar, Zeiss, Jena, Germany) in combination with Cell^D (Soft Imaging System, 
Berlin, Germany) and ImageJ software (freeware). CD3+, CD4+, CD8+ and IL-17A+ T- cells were counted at 100x 
magnification. After generating a grid (ImageJ software; area per point: 50.000 pixels^2), all stained/unstained 
cells were counted in three squares adjacent to basal membrane zone (ImageJ, cell counter; Fig. 6).
Statistcal Analyses. The study has been registered in the DRKS (Deutsches Register Klinischer Studien), 
Registration Number DRKS00017540, accepted registration 01.07.2019. (WHO website: http://apps.who.int/
trialsearch/).
Accession code. For statistical analyses the statistical unit was the patient and the main outcome variable was 
the reduction of the lesion size. Secondary variables were changes in the lesion scores, QOL symptoms, ABSIS 
Figure 6. Analysis of T lymphocyte subsets in OLP lesions. The T- cell infiltrate of mucosal sections was 
quantified by microscopical images (Axiostar, Zeiss, Jena, Germany) in combination with Cell^D (Soft Imaging 
System, Berlin, Germany) and ImageJ software (freeware). T cells were counted at a 100x magnification. After 
generating a grid (ImageJ software; area per point: 50.000 pixels^2), all stained T- cells were counted in three 
squares adjacent to basal membrane zone (ImageJ, cell counter) and their proportion of all infiltrating cells was 
determined subsequently.
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I and II scores and changes in the numbers of peripheral blood T- cell subsets (CD8+, CD4+, CD8+CCR4+, 
CD4+CCR4+, CD8+CD137+, CD4+CD137+, IFNγ+, IL-5+, IL-17a+). For all pairwise comparisons of ABSIS 
scores, lesion size and cell counts between time points generalized least squares (GLS) estimations were used. 
In the case of the ordinally scaled lesions scores50,51 as well as the non-normally distributed QOL scores, 
non-parametric Friedman test were used to test for a tendency toward higher scores between time points. For 
the multivariate comparison of QOL scores between day 0 and day 56 the multivariate extension of the Friedman 
test was applied. P-values were calculated adjusted for multiple comparisons and the level of significance was set 
at 0.05.
Data availability
Study protocol data are available https://www.drks.de/ui_data_web/DrksUI.html?locale=de, http://apps.who.int/
trialsearch/. Data results are available from arweiler@med.uni-marburg.de, ralucacosgrea@gmail.com.
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